
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is benefiting from a powerful Filspari launch, with 3Q26 US net sales of $200.2M, up 120% year over year and 42% sequentially, while patient start forms of 1,932 still left room for further FSGS penetration as conversion to paid therapy improves. The company also looks well supported by a durable rare-disease franchise, with management guiding to more than $3B in total peak US sales by 2033 and recent patent allowance extending FSGS method-of-use protection into October 2037, which strengthens long-term exclusivity. Beyond the core product, a $471.8M cash position, a capital-efficient model, and pipeline catalysts for pegtibatinase in 2H27 and civorebrutinib by year-end 2026 add multiple avenues for upside.
Bears say
Travere Therapeutics is facing an unattractive risk-reward profile because valuation depends heavily on a narrow set of products and pipeline assets, while commercial, clinical, and regulatory setbacks across Thiola, Filspari, and development programs could materially impair prospects. The company reported $489.2M in cash, cash equivalents and marketable securities at the end of 1Q 2026 and $471.8M at the end of 3Q 2026, but that liquidity does not eliminate the need for additional capital if execution falters, leaving shareholders exposed to dilution from a follow-on stock offering. Any delays or disappointments in commercializing Filspari or pegtibatinase could reduce sales potential and undermine confidence in the company’s long-term valuation.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Travere Therapeutics (TVTX) Forecast
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares